Table of Contents
National Immunization Survey-Teen (NIS-Teen) 2020, Texas
Immunization Coverage Among
Texas Teens 13-17 Years Old
Source:
CDC
NIS-Teen Report
About
the National Immunization Survey-Teen (NIS-Teen)
The NIS-Teen is a national survey
conducted every year by the Centers for Disease Control and Prevention (CDC) to
assess vaccination coverage levels, or the percentage of people vaccinated,
among adolescents 13-17 years of age. This study collects data by interviewing
households in all 50 states, the District of Columbia, and smaller selected
areas. The interviews are conducted by telephone, with households selected at
random. To ensure the accuracy of vaccination coverage estimates, participant vaccination
records are collected from healthcare providers by mail after the interview.
The parents and guardians of eligible teens are asked during the telephone
interview for consent to contact the adolescents’ vaccination providers to
verify their records.
The NIS-Teen was established to provide
an ongoing and consistent data set for analyzing vaccination coverage levels
among adolescents in the United States and to share this information with
interested public health partners. The NIS-Teen provides national and statewide
estimates of vaccination coverage, including new vaccines as they are licensed
and recommended for use. It also helps track progress towards the Healthy
People 2030 goals.
Survey
Sample
The survey assessed the vaccination
histories of approximately 20,000 U.S. adolescents aged 13-17 years between
January 2020 and February 2021. These adolescents were born between January 2002
and February 2008. A total of 1,141 Texas
teens were interviewed as part of this study, with estimated vaccination
coverage levels for the state of Texas and two local Texas areas – the City of
Houston and Bexar County.
Vaccines Included
The
following vaccine doses routinely recommended for adolescents starting at 11-12
years of age, were measured in the 2020 NIS-Teen:
- ≥1 dose of Tetanus-diphtheria-pertussis
(Tdap) vaccine
- ≥1 dose of Quadrivalent
Meningococcal Conjugate (MenACWY) vaccine
- ≥1 dose of human
papillomavirus (HPV) vaccine
- HPV vaccine, Up-to-Date,
either two or three doses dependent on age of initiation
- Hepatitis A (HepA)
vaccination, newly added to the NIS-Teen survey for 2020. In July 2020, Advisory
Committee on Immunization Practices (ACIP) revised recommendations for
HepA vaccination to include catch-up vaccination for children and
adolescents aged 2–18 years who have not previously received HepA vaccine.
Vaccination Coverage Levels
NIS-Teen Immunization Coverage Estimates in the U.S and Texas, 2019-2020 |
Vaccine | U.S. 2020 | Texas 2019 | Texas 2020 | 2019 to 2020 Texas Percentage Point Change |
≥1 dose of
tetanus-diphtheria-acellular pertussis (Tdap) | 90.1% | 84.8% | 84%c | -0.8% |
≥1 dose of meningococcal
conjugate (MenACWY) | 89.3% | 85.9% | 91.2% | 5.3%b |
≥1 dose of human papillomavirus (HPV) | 75.1% | 65.1% | 72.8%% | 7.7% b |
HPV Up-To-Date (HPV UTD) | 58.6% | 48.4% | 54.9% | 6.5% b |
≥1 dose of HPV, females | 77.1% | 64.2% | 76.1% | 11.9%b |
HPV UTD, females | 61.4% | 50.6% | 57.0% | 6.4% |
≥1 of HPV, males | 73.1% | 65.9% | 69.6% | 3.8% |
HPV UTD, males | 56.0% | 46.3% | 52.9% | 6.6% |
≥2 doses of measles, mumps,
rubella (MMR) | 92.4% | 84.2% | 85.9% c | 1.7% |
≥2 doses of varicella (VAR) | 91.9% | 81.6% | 86.7%c | 5.1% b |
≥2 HepA | 82.1% | 81.4% | 87.1%a | 5.7% b |
a Significantly
greater (p<.0.05) than the U.S. estimate
b Statistically
significant difference (p<0.05) between years
c
Significantly
lower (p<0.05) than the U.S. estimate
See accessible data table of chart below:
NIS-Teen Immunization Coverage Estimates for Tdap and MenACWY by Jurisdiction, 2020 |
Vaccine | US | Texas | City of Houston | Bexar County |
≥1 Tdap | 90.1% | 84% | 87.6% | 87.2% |
≥1 MenACWY | 89.3% | 91.2% | 89.2% | 90.6% |

See accessible data table of chart below:
NIS-Teen Immunization Coverage Estimates for HPV by Gender and Jurisdiction, 2020 |
Vaccine | US | Texas | City of Houston | Bexar County |
≥1 HPV, females | 77.1% | 76.1% | 87.6% | 77.2% |
HPV UTD, females | 61.4% | 57% | 72.5% | 62.1% |
≥1 HPV, males | 71.3% | 69.6% | 67% | 74.2% |
HPV UTD, males | 56.% | 52.9% | 49.8% | 59.4% |

a The same methodology was not used for all years.
See accessible data table of chart below:
NIS-Teen One-Dose HPV Immunization Coverage Estimates by Gender, U.S. and Texas, 2011-2020a |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
U.S, Female | 53.0% | 53.8% | 56.7% | 60.0% | 62.8% | 65.1% | 68.6% | 69.9% | 73.2% | 77.1% |
Texas, Female | 48.8% | 51.2% | 55.5% | 50.7% | 60.1% | 54.5% | 60.4% | 64.6% | 64.2% | 73.1% |
U.S, Male | 8.3% | 20.8% | 33.6% | 41.7% | 49.8% | 56.0% | 62.6% | 66.3% | 69.8% | 73.1% |
Texas, Male | 10.4% | 24.0% | 33.7% | 36.6% | 41.4% | 44.3% | 55.2% | 55.5% | 65.9% | 69.6% |
a The same methodology was not used for all years.
View survey results from prior years:
2019 National Immunization Survey Results
2018 National Immunization Survey Results
2017 National Immunization Survey Results
2016 National Immunization Survey Results
2015 National Immunization Survey Results
2014 National Immunization Survey Results
2013 National Immunization Survey Results
2010 National Immunization Survey Results
2009 National Immunization Survey Results
2008 National Immunization Survey Results
2007 National Immunization Survey Results
2006 National Immunization Survey Results
2005 National Immunization Survey Results
2004 National Immunization Survey Results
2003 National Immunization Survey Results
2002 National Immunization Survey Results
2001 National Immunization Survey Results
2000 National Immunization Survey Results